Kardiologia Polska, the esteemed journal of the Polish Cardiac Society, has established itself as a vital resource in the field of cardiology and cardiovascular medicine since its inception in 1954. With an ISSN of 0022-9032 and an E-ISSN of 1897-4279, this journal serves as a platform for groundbreaking research and scholarly articles that contribute to the advancement of heart health. Although currently not an open access journal, it remains an essential reference for practitioners and researchers seeking to stay abreast of the latest developments in cardiovascular science. The journal reflects its scholarly depth through a Category Quartile of Q3 and a commendable Scopus ranking at the 48th percentile in its field. Published primarily in Poland, it caters to a global audience eager to explore comprehensive studies spanning clinical cardiology, innovative therapeutic approaches, and emerging cardiovascular trends. Join a thriving academic community by engaging with the invaluable insights and research contributions found within the pages of Kardiologia Polska.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Journal of Cardiovascular and Thoracic Research is a premier open access journal published by Tabriz University of Medical Sciences & Health Services, focusing on the dynamic fields of cardiology and cardiovascular medicine. With an ISSN of 2008-5117 and E-ISSN 2008-6830, the journal provides a platform for innovative research and advances in cardiovascular and thoracic health, catering to a global audience of researchers, healthcare professionals, and students. Since its inception as an open access publication in 2010, the journal has established itself within the academic community, evidenced by its inclusion in Scopus and its category quartile ranking (Q3) in 2023. Located in Tabriz, Iran, the journal aims to disseminate high-quality studies that contribute to the understanding and treatment of cardiovascular diseases, thus enabling advancements in this critical field of medicine. With a Scopus rank of 248 out of 387 in the category of Cardiology and Cardiovascular Medicine, the Journal of Cardiovascular and Thoracic Research is dedicated to fostering collaboration and dialogue among researchers and practitioners, promoting a deeper understanding of cardiovascular and thoracic health.

Current Cardiology Reports, published by Springer, is a leading peer-reviewed journal dedicated to advancing the field of cardiology and cardiovascular medicine. With its ISSN 1523-3782 and E-ISSN 1534-3170, the journal offers a platform for researchers and practitioners to share innovative research findings, clinical insights, and comprehensive reviews, contributing to the ongoing dialogue in cardiovascular health. Recognized for its high impact, Current Cardiology Reports holds a prestigious Q1 ranking in the Cardiology category for 2023 and ranks #83 out of 387 in Scopus, placing it in the 78th percentile among journals in its field. The journal, converging its insights from 1999 to 2024, aims to disseminate valuable knowledge that can inform clinical practice and influence future research directions. Although not an Open Access journal, the rich content and timely articles published within its pages are invaluable to both seasoned professionals and emerging scholars in cardiology. Based in New York, United States, the journal continues to play a critical role in shaping cardiovascular medicine through rigorous scientific inquiry and education.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

Medical Oncology, published by Humana Press Inc, stands as a significant contributor to the field of oncology, with its long-standing commitment to disseminating research and clinical findings relevant to the treatment and management of cancer. Established in 1994 and continuing through 2024, this journal publishes insightful articles that reflect the latest advancements in cancer research, hematology, and related medical fields. With an evolving impact factor and remarkable categorizations, including Q3 in Cancer Research and Q2 in both Hematology and Oncology, Medical Oncology serves as a pivotal resource for healthcare providers, researchers, and students dedicated to improving cancer outcomes. Although it does not offer open access, the journal is widely recognized for its rigorous peer-review process and high-quality publications, making it an essential platform for sharing innovative research and critical reviews in oncology.

TEXAS HEART INSTITUTE JOURNAL, published by the renowned Texas Heart Institute, stands as a pivotal resource in the field of cardiology and cardiovascular medicine. With a history spanning over four decades since its establishment in 1982, this journal addresses a wide range of topics within its scope, including clinical studies, innovative treatments, and groundbreaking research in heart health. Despite its Q3 ranking in both Cardiology and Cardiovascular Medicine, the journal is committed to fostering advancement in medical knowledge and practice, providing an essential platform for healthcare professionals and researchers alike. While currently lacking open access, the journal is recognized for its contributions to the field, aiming to illuminate critical healthcare discussions and promote the exchange of ideas. For those interested in staying at the forefront of cardiovascular research, TEXAS HEART INSTITUTE JOURNAL offers invaluable insights and the latest developments shaping the future of heart care.